Traynor Capital Management Inc. Acquires 2,101 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Traynor Capital Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 29.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 9,350 shares of the biopharmaceutical company’s stock after purchasing an additional 2,101 shares during the period. Traynor Capital Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $2,200,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the business. Huntington National Bank increased its holdings in shares of Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 45 shares during the period. Hollencrest Capital Management bought a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $29,000. Washington Trust Advisors Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $42,000. True Wealth Design LLC grew its holdings in shares of Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 153 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at $45,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the transaction, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the completion of the sale, the chief executive officer now owns 78,880 shares in the company, valued at approximately $19,797,302.40. The trade was a 6.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,122 shares of company stock valued at $2,540,455 over the last 90 days. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $266.54 on Thursday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The company has a market cap of $34.38 billion, a price-to-earnings ratio of -101.73 and a beta of 0.34. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The company’s 50 day moving average is $245.91 and its 200 day moving average is $259.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same quarter last year, the business posted $1.15 EPS. The business’s quarterly revenue was down 33.3% compared to the same quarter last year. On average, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.18 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on ALNY. Raymond James boosted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. Scotiabank lifted their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. HC Wainwright restated a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. StockNews.com lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 9th. Finally, Wolfe Research downgraded shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $298.61.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.